
PRESCRIBED SAFER SUPPLY PROGAMS

Rebecca Penn, Project Manager London InterCommunity Health Centre February 13, 2024



National Safer Supply Community of Practice La communauté de pratique nationale sur l'approvisionnement plus sécuritaire



NATIONAL SAFER SUPPLY COMMUNITY OF PRACTICE

- Goal: Support the scale up of PSS programs through capacity building and knowledge exchange
- **Focus:** Medical model (e.g., provided by prescription) that is delivered from a harm reduction and public health approach while supporting advocacy for non-medical models and decriminalization.
- Values: Respect, collaboration, integrity, and curiosity
- **Activities:** Prescriber consultation service, role meetings, working groups, drop-in meeting, webinars, workshops, consultations, resource development.




What is the problem?


Belleville declares addiction emergency after latest overdose surge

Eastern Ontario city says 23 people overdosed since Tuesday afternoon




Dan Taekema · CBC News · Posted: Feb 08, 2024 4:00 AM EST | Last Updated: February 8





Fentanyl

Fentanyl and unexpected noteworthy drugs found in expected fentanyl substances over time



Substances involved in opioid toxicity deaths in Ontario, 2018-2023 (Q1-Q3)


	% of Opioid Toxicity Deaths by Year					
	2040	2040	2020	2024	2022	2023 (Q1
	2018	2019	2020	2021	2022	- Q3)
Non-Pharmaceutical Opioids						
Total fentanyl/Fentanyl analogues	67.9	75	85.7	88.9	83.4	86.4
Fentanyl	64.4	53.4	85.5	87.9	81.7	82.5
Carfentanil	6.3	31.4	0.5	4.3	7.6	3.7
Fluorofentanyl	0	0	0	0.1	1.3	20.5
Other Fentanyl Analogues**	1.4	1.3	1.2	0.4	0.5	0.6
Nitazenes*	0	0	0	0.2	0.8	0.3
Heroin	7.2	4.1	1.7	0.8	0.3	0.7
Opioids Indicated for Pain						
Codeine	4.6	2.6	1.8	1.4	1.4	1.3
Oxycodone	11.1	9.1	4.9	3.8	5.7	4.4
Hydromorphone	10.8	10.1	6.1	5.9	7	7.1
Tramadol	1.1	0.6	0.4	0.2	0.4	0.4
Morphine	10.7	8	5.2	4	5.7	5.4
Opioid Agonist Treatment						
Methadone	12.9	12.9	10.4	10.3	9.7	8
Buprenorphine	0.1	0.3	0.3	0.1	0.1	0.3
Other Substances						
Total Stimulant(s)	43.4	48.2	56.9	59.3	59.8	66.5
Methamphetamine	16.3	20.5	25.8	30.3	32.1	34.6
Cocaine	32.2	34.4	41.6	40	39.4	47.4
Other Stimulants	2.4	1.4	1.7	1.2	1.4	2.1
Alcohol	13.7	12.6	12.8	10.6	12.3	11.7
Benzodiazepines	0	0	0	4.1	10.9	28.7
Detection of nonpharmaceutical benzodiazepines*	32.7	29.8	45.1	64.1	47.9	63.7
Detection of nonpharmaceutical benzoalazepines Detection of xylazine*	0	0	0.2	2.1	2.5	2.7
**Includes Para-fluorobutyryl Fentanyl, Cyclopropylfent						

^{**}Includes Para-fluorobutyryl Fentanyl, Cyclopropylfentanyl, Furanylfentanyl, Despropionyl Fentanyl, Furanyl UF 17, Methylfentanyl, and Acetylfentanyl

Fentanyl continues to contribute to the majority (83%) of opioid toxicity deaths. **Stimulants** are involved in nearly 7 in 10 opioid toxicity deaths.




Opioid toxicity deaths in Ontario by year, 2003-2023 (Q1 - Q3)



In **2021**, the mortality rate for opioid toxicity in Ontario was 19.3 per 100,000 population; more than double the rate in 2017 (9.1).

In 2023 (Q1-Q3), the mortality rate has decreased by 9% compared to 2021, however remains 64% higher than in 2019.



Safe Supply / Prescribed Safer Supply

- People who use drugs have been calling for safer supply for decades
- See CAPUD's concept document (2019)
- Different models
 - Medical models, i.e., prescribed safer supply, prescribed alternatives, risk mitigation guidance
 - Non-medical models, e.g., compassion clubs see DULF






National Safer Supply Community of Practice La communauté de pratique nationale sur l'approvisionnement plus sécuritaire

Prescribed Safer Supply / Prescribed Alternatives

- 2016 LIHC daily dispensed
- 2019 Health Canada's Safe Supply Implementation Task Team
- 2020 5 projects funded; start of Risk Mitigation Prescribing in BC
- 2024 24 projects funded, 22 have funding expiring March 2024

Medical models:

- Purpose: Risk mitigation, treatment, harm reduction
- Approach: Witnessed dosing, unobserved dosing
- Setting: Program vs non-program





National Safer Supply Community of Practice
La communauté de pratique nationale sur
l'approvisionnement plus sécuritaire

Ontario SUAP funded programs

15 PSS Programs in Ontario – Approx. 1500 participants

- Toronto: The Works (iOAT); Parkdale Queen West CHC; South Riverdale CHC;
 Sherbourne Health Centre; Inner City FHT
- Brantford: Grand River CHC
- Guelph: Guelph CHC
- Hamilton: Hamilton Urban Core CHC; HAMSMaRT
- Kitchener Waterloo: K-W Working Centre-Sanguen
- London: London InterCommunity Health Centre
- Thunder Bay: NorWest Community Health Centres
- Ottawa: Pathways to Recovery
- Peterborough: 360 Degree NPLC
- Niagara: REACH





Ontario CHC Program Characteristics

- Based in community health settings
- Provided by interdisciplinary teams, including PWLLE
- Clinical substance use health and primary care
- Wraparound supports
- Daily dispensed take-home short-acting (Dilaudid 8mg tablets)
 alongside daily dispensed observed long-acting (slow-release oral
 morphine, methadone)
- Undertake program evaluations and many participate in external research studies





Ontario CHC PSS Client Characteristics

Eligibility criteria

OUD, previous OAT, regular use of unregulated supply

Triage criteria

 High risk of harm, detached from care, BIPOC, women and gender diverse, engaged in sex work, pregnant, medically and socially complex

Client Characteristics

- highly vulnerable group whose needs are currently unmet by existing OAT and RAAM models, Houseless/precariously housed
- Complex physical and/or mental health problems
- Previous experiences with OAT have been unsuccessful
- Involved in high-risk activities and criminalized activities
- Hx of frequent overdoses
- Income and food insecurities





Emerging Evidence

Highlights:

- Reduced risk of overdose
- Reduced mortality
- Decline in health care costs
- Fewer hospital visits
- Increased engagement and retention in care
- Improvements in physical and mental health
- Improvements in social well-being and stability
- Reduced use of unregulated drugs
- Improved control over drug use
- Reduced engagement in criminalized activities

See NSSCoP Evidence Brief for summary of 24 studies (peer reviewed and grey lit)






Emerging Evidence

Challenges

- Lack of sustainable funding
- Huge demand few programs and limited program capacity
- Limited medication options that do not properly match clients' needs
- Politicization of safer supply and harm reduction
- Lack of affordable, appropriate housing
- Medical model is a barrier for some
- Rural and remote communities
- Continuity of care (hospitals, carceral settings)

















"There are people that are on this program that started off in tents and now they've actually got themselves to a position where they're renting an apartment. That doesn't happen without safer supply."


IT CHANGED MY LIFE.

"It's been a miracle...it's made me love life. It's given me a reason to get out of bed. It's changed my whole perspective on life."

Check out our website

- Regularly updated <u>evidence brief</u>
- Program evaluation reports
- Discussion tools
- Program policies and protocols
- Hot Topic Webinar Archive
- Research Spotlight Webinar Archive
- Searchable substance use health Resource library with 1800+ items
- Upcoming events
- To access our <u>prescriber consultation service</u>
- To join <u>our Listserv and membership</u>







The Ethics of Prescribed Safer Supply Ethics [eth'iks] n. moral choices to February 29 lue of human C ciples that o **RSVP for Link** National Safer Supply Community of Practice



JOIN OUR COMMUNITY NSS-APS.CA

Visit our website and click "Join" to register as a member!



